Loading...
XKRX
004720
Market cap37mUSD
Jul 10, Last price  
3,050.00KRW
1D
-0.65%
1Q
-18.77%
Jan 2017
-82.32%
Name

PharmGen Science Inc

Chart & Performance

D1W1MN
XKRX:004720 chart
P/E
—
P/S
0.32
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.89%
Rev. gr., 5y
12.37%
Revenues
173.07b
+1.04%
78,559,320,00077,680,145,00048,740,944,00043,926,893,00027,911,913,08030,291,620,67038,971,052,56044,203,012,42060,405,445,20071,545,613,18079,894,496,57089,101,640,00095,137,668,55096,614,310,440109,866,067,000150,930,715,000166,778,826,000171,286,610,000173,072,508,000
Net income
-116.64b
L
-221,835,000-11,315,404,000-1,946,753,000-2,765,635,000-8,823,738,000-5,231,609,800-3,698,557,000-4,583,680,0002,067,281,0003,452,135,9304,319,900,3104,467,984,120235,995,6009,222,178,37032,465,959,00070,059,662,0005,727,239,0002,790,819,000-116,641,028,000
CFO
5.32b
+123.20%
-5,533,603,0003,823,582,000-14,702,708,000628,491,0002,893,279,980-3,975,637,310-4,204,856,380-2,016,894,3203,621,572,7407,754,655,7901,837,763,3804,215,582,0902,523,396,0002,675,612,0007,784,093,000-1,286,177,0005,438,941,0002,384,289,0005,321,836,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PharmGen Science, Inc., originally founded in 1961 as Wooridul Pharmaceutical Limited, is a South Korean company primarily involved in the research, development, manufacturing, and distribution of pharmaceutical products. Based in Hwaseong, South Korea, the firm offers a diverse portfolio encompassing prescription medications, over-the-counter drugs, nutritional supplements, and cosmetic items. These are available in various forms, including tablets, hard capsules, granules, ointments, syrups, and suspensions.
URL
http://www.wooridulpharm.com/
IPO date
Jun 15, 1990
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT